Tab. 3  Rezidivhäufigkeiten und -lokalisationen.

	UKE			CaRE-1
Lokalisation	Total (n = 21 Pt.)	N − pelvin (n = 15 Pt.)	N+ pelvin (n = 6 Pt.)	Total (n = 70 Pt.)	N− pelvin (n = 43 Pt.)	N+ pelvin (n = 14 Pt.)	Status unbekannt (n = 13 Pt.)
Pt. = Patientinnen
Anzahl der Rezidive	5 (23,8%)	2 (13,3%)	3 (50%)	30 (42,9%)	17 (39,5%)	8 (57,1%)	5 (38,5%)
kein Rezidiv	16 (76,2%)	13 (86,6%)	3 (50%)	32 (45,7%)	22 (51,2%)	4 (28,6%)	6 (46,2%)
Vulva	2 (9,5%)	2 (13,3%)	0	15 (21,4%)	10 (23,3%)	3 (21,4%)	2 (15,4%)
Leiste	1 (4,8%)	0	1 (16,6%)	1 (1,4%)	1 (2,3%)	0	0
Vulva + Leiste	0	0	0	3 (4,3%)	0	1 (7,1%)	2 (15,4%)
Becken (± andere)	0	0	0	4 (5,7%)	3 (7%)	0	1 (7,7%)
Fernmetastasierung (± andere)	2 (9,4%)	0	2 (33,3%)	7 (10%)	3 (7%)	4 (28,6%)	0